Novo Nordisk Not Unnerved By ‘Quarterly Blip’
Executive Summary
Sales of Wegovy and Ozempic were strong again in the second quarter and while they were shy of analyst expectations, the Copenhagen-based giant is confident of continuing demand despite competition from Eli Lilly’s Zepbound.